A novel role of dapagliflozin in mitigation of acetic acid-induced ulcerative colitis by modulation of monocyte chemoattractant protein 1 (Mcp-1)/nuclear factor-kappa b (nf-κb)/interleukin-18 (il-18)

12Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Colon illnesses, particularly ulcerative colitis, are considered a major cause of death in both men and women around the world. The present study investigated the underlying molecular mechanisms for the potential anti-inflammatory effect of Dapagliflozin (DAPA) against ulcerative colitis (UC) induced by intracolonic instillation of 3% v/v acetic acid (AA). DAPA was administered to rats (1 mg/kg, orally) for two weeks during the treatment regimen. Interestingly, compared to the normal group, a marked increase in the index of colon/body weight, colon weight/colon length ratio, serum lactate dehydrogenase (LDH), and C-reactive protein (CRP), besides decrease in the serum total antioxidant capacity (TAC), were reported in the AA control group (p < 0.05). Eleva-tion in colon monocyte chemoattractant protein (MCP1), Interleukin 18 (IL-18), and inflammasome contents were also reported in the AA control group in comparison with the normal group. In addition, colon-specimen immunohistochemical staining revealed increased expression of nuclear factor-kappa B (NF-κB) and Caspase-3 with histopathological changes. Moreover, DAPA significantly (p < 0.05) reduced the colon/body weight index, colon weight/colon length ratio, clinical evaluation, and macroscopic scoring of UC, and preserved the histopathological architecture of tissues. The inflammatory biomarkers, including colon MCP1, IL-18, inflammasome, Caspase-3, and NF-κB, were suppressed following DAPA treatment and oxidants/antioxidants hemostasis was also restored. Col-lectively, the present data demonstrate that DAPA represents an attractive approach to ameliorating ulcerative colitis through inhibiting MCP1/NF-κB/IL-18 pathways, thus preserving colon function. Antioxidant, anti-inflammatory, and anti-apoptotic properties of DAPA are implicated in its observed therapeutic benefits.

Cite

CITATION STYLE

APA

Elmahdy, M. K., Antar, S. A., Elmahallawy, E. K., Abdo, W., Hijazy, H. H. A., Albrakati, A., & Khodir, A. E. (2022). A novel role of dapagliflozin in mitigation of acetic acid-induced ulcerative colitis by modulation of monocyte chemoattractant protein 1 (Mcp-1)/nuclear factor-kappa b (nf-κb)/interleukin-18 (il-18). Biomedicines, 10(1). https://doi.org/10.3390/biomedicines10010040

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free